Drug Database
Back to search

Netherlands· NL-396ed8a18f19

Otezla 20 mg, filmomhulde tablet

A apremilast product containing apremilast, registered in Netherlands by Amgen Europe B.V.. The same ATC class is registered in 18 of our 19 countries.

ATC L04AA32

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOtezla 20 mg, filmomhulde tabletATCL04AA32REGISTER NO.NL-396ed8a18f19PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about apremilastAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Apremilast is registered in 18 of 19 countries.

Countries holding a registration under ATC L04AA32 (apremilast), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search apremilast products by name

Apremilast · ATC L04AA32

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apremilast costs, country by country.

Normalised to the WHO defined daily dose (60 mg), the median price runs from $13.92 in Switzerland to $51.51 in Italy — a ×3.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Apremilast · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • IT Italy$51.51
  • CZ Czechia$51.22
  • FR France$22.59
  • CH Switzerland$13.92
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
APREMILAST
Manufacturer
Amgen Europe B.V.
Country
Netherlands (NL)
ATC code
L04AA32
ATC class
Apremilast
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/981

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for apremilast.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check apremilast against other medicinesHow interaction checks work

Apremilast · interactions on record

82 records

  • 11 severe
  • 69 moderate
  • 2 minor

Most severe, free to view

  • RifampicinJ04AB02severe
  • MitotaneL01XX23severe
  • EnzalutamideL02BB04severe
  • ApalutamideL02BB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apremilast in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apremilast products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Apremilast +pharma, Apremilast Devatis
  • Belgium · Apremilast Eg, Apremilast Hcs
  • Bulgaria · Тивлемак
  • Cyprus · Apremilast Ebewe, Apremilast Sandoz
  • Czechia · Apremilast +pharma, Apremilast Belupo
  • Germany · Apremilast, Apremilast 089pharm
  • Denmark · Apremilast Devatis, Apremilast Stada
  • Estonia · Apremilast Krka, Apremilast Stada
  • Spain · Apremilast, Apremilast Aurovitas Spain
  • Finland · Apremilast Avansor, Apremilast Bioglan
  • France · Apremilast Arrow, Apremilast Biogaran
  • United Kingdom (Northern Ireland) · Apremilast, Apremilast Amarox
  • Greece · Afimax, Apremilast Anabiosis
  • Croatia · Aperzyx, Apremilast Belupo
  • Hungary · Apremilast Kezdőcsomag Stada, Apremilast Krka
  • Ireland · Apremilast 30mg Tablets, Apremilast Aurobindo
  • Iceland · Apremilast Accord, Apremilast Aristo
  • Italy · Apremilast Day Zero, Apremilast Dr. Reddy’s
  • Liechtenstein · Apremilast Accord
  • Lithuania · Apremilast Krka, Apremilast Stada
  • Luxembourg · Apremilast Eg
  • Latvia · Apremilast Krka, Apremilast Stada
  • Malta · Apremilast, Apremilast Clonmel
  • Norway · Apremilast Accord, Apremilast Devatis
  • Poland · Apremilast Aristo, Apremilast Farmaprojects
  • Portugal · Apremilaste Humanis
  • Romania · Apremilast Stada
  • Sweden · Apremilast Anabiosis, Apremilast Avansor
  • Slovenia · Apremilast Belupo, Apremilast Elpen
  • Slovakia · Apremilast Belupo, Apremilast Hcs

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bc2425fa-99a9-44b4-aaed-93eb975db8ec
GET /v1/drugs/bc2425fa-99a9-44b4-aaed-93eb975db8ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/otezla-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Apremilast",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp114859",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "APREMILAST"
  ],
  "leaflet_url": null,
  "authorised_at": "2015/01/15",
  "procedure_number": "EMEA/H/C/003746",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/981",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about apremilast.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console